Comparison · NCT00319982-3989272f
I- Diltiazem vs II- Placebo: Development of Left Ventricular Hypertrophy
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. I- Diltiazem vs II- Placebo: Development of Left Ventricular Hypertrophy. Trial comparisons, record NCT00319982-3989272f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00319982-3989272f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.111 | 0.031 | 0.328 | wilson | |
| Risk in group 2 | 0.1 | 0.0279 | 0.301 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0111 | -0.205 | 0.24 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.11 | 0.174 | 7.09 | log | |
| Odds ratio, group 1 over group 2 | 1.13 | 0.142 | 8.94 | log | |
| Number needed to treat, for one more participant with the outcome on I- Diltiazem than on II- Placebo | 90 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | I- Diltiazem | Diltiazem: Titrated to a target dose of 360 mg daily (sustained release formulation) for the duration of the study period | 2 | 18 | OG000 |
| Group 2 | II- Placebo | Placebo Comparator~Placebo: Placebo comparator (double-blind allocation of study medication) | 2 | 20 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Development of Left Ventricular Hypertrophy
- Description
- The number of participants who developed overt left ventricular hypertrophy during the duration of the trial was analyzed
- Time frame
- Baseline through final study visits
- Population
Source ClinicalTrials.gov
Trial
- Title
- Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem
- NCT number
- NCT00319982
- Phases
- PHASE2, PHASE3
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Diltiazem, Placebo
- Lead sponsor
- Brigham and Women's Hospital
- Results first posted
- 2015-04-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00319982?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00319982-3989272f